These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32979427)

  • 1. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
    Yu J; Zhou Z; Mahaffey KW; Matthews DR; Neuen BL; Heerspink HJL; Jardine MJ; Li J; Perkovic V; Neal B; Arnott C
    Int J Cardiol; 2021 Feb; 324():165-172. PubMed ID: 32979427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
    Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
    Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
    Cherney DZI; Dagogo-Jack S; McGuire DK; Cosentino F; Pratley R; Shih WJ; Frederich R; Maldonado M; Liu J; Wang S; Cannon CP;
    Clin Cardiol; 2021 Aug; 44(8):1139-1143. PubMed ID: 34129237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
    Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Savvanis S; Antoniou VK; Memi E
    Curr Cardiol Rev; 2020; 16(4):258-265. PubMed ID: 31362691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiorenal protection with SGLT2 inhibitors (gliflozins) : from EMPA-REG OUTCOME to CANVAS].
    Scheen AJ; Ernest P; Jandrain B
    Rev Med Suisse; 2017 Aug; 13(571):1421-1426. PubMed ID: 28837279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.
    Smidt LCA; Visseren FLJ; de Ranitz-Greven WL; Nathoe HM; Kappelle LJ; de Borst GJ; de Valk HW; Westerink J;
    Cardiovasc Diabetol; 2021 Sep; 20(1):181. PubMed ID: 34496847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
    Shao H; Shi L; Fonseca VA
    Diabetes Care; 2020 Jul; 43(7):1530-1536. PubMed ID: 32345650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk.
    Schernthaner G; Groop PH; Kalra PA; Ronco C; Taal MW
    Diabetes Obes Metab; 2020 Jul; 22(7):1024-1034. PubMed ID: 32037647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men.
    Rådholm K; Zhou Z; Clemens K; Neal B; Woodward M
    Diabetes Obes Metab; 2020 Feb; 22(2):263-266. PubMed ID: 31486272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV].
    Scheen AJ
    Rev Med Suisse; 2020 Aug; 16(703):1483-1488. PubMed ID: 32852168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
    Sridhar VS; Rahman HU; Cherney DZI
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():55-68. PubMed ID: 32267075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.